The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Persubstituted Cyclodextrin-Based Glycoclusters as Inhibitors of Protein−Carbohydrate Recognition Using Purified Plant and Mammalian Lectins and Wild-Type and Lectin-Gene-Transfected Tumor Cells as Targets
Abstract
Multivalent glycoclusters have the potential to become pharmaceuticals by virtue of their target specificity toward clinically relevant sugar receptors. Their application can also provide fundamental insights into the impact of two spatial factors on binding, i.e., topologies of ligand (branching mode, cluster presentation) and carbohydrate recognition domains in lectins. Persubstituted macrocycles derived from nucleophilic substitution of iodide from heptakis 6-deoxy-6-iodo-beta-cyclodextrin by the unprotected sodium thiolate of 3-(3-thioacetyl propionamido)propyl glycosides (galactose, lactose and N-acetyllactosamine) were prepared. The produced glycoclusters were first tested as competitive inhibitors in solid-phase assays. A plant toxin from mistletoe and an immunoglobulin G fraction from human serum were markedly susceptible. A nearly 400-fold increase in inhibitory potency of each galactose moiety in the heptavalent form relative to free lactose (217-fold relative to free galactose) was detected. Thus, these glycoclusters can efficiently interfere, for example, with xenoantigen-dependent hyperacute rejection. Among the tested galectins selected from this family of adhesion- and growth-regulatory endogenous lectins, the substituted beta-cyclodextrins acted as sensors to delineate topological differences between the two dimeric prototype proteins. The relatively strong reactivity with chimera-type galectin-3, a mediator of tumor metastasis, disclosed selectivity for glycocluster binding among galectins. Equally important, the geometry of ligand display (maxiclusters, bi- or triantennary N-glycans) made its mark on the inhibitory potency. To further determine the sensitivity of a distinct galectin presented on the cell surface and not in solution, we established a stably transfected tumor cell clone. We detected a significant response to presence of the multivalent inhibitor. This type of chemical scaffold with favorable pharmacologic properties might thus be exploited for the design of galectin- and ligand-type-selective glycoclusters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eukaryotic glycosylation: whim of nature or multipurpose tool?
Reuter, G., & Gabius, H.-J. (1999) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050298 · Cited by 233
Self-citation
Cited by
Galectin-1: a small protein with major functions
Camby, I., Le Mercier, M., Lefranc, F., & Kiss, R. (2006) · Glycobiology · doi:10.1093/glycob/cwl025 · Cited by 893
Chemical Biology of the Sugar Code
Gabius, H., Siebert, H., André, S., Jiménez‐Barbero, J., & Rüdiger, H. (2004) · ChemBioChem · doi:10.1002/cbic.200300753 · Cited by 524
Self-citationSupramolecular Chemistry of Cyclodextrins in Enzyme Technology
Villalonga, R., Cao, R., & Fragoso, A. (2007) · Chemical Reviews · doi:10.1021/cr050253g · Cited by 370
Glycopolymer Nanobiotechnology
Miura, Y., Hoshino, Y., & Seto, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00247 · Cited by 321
López-Lucendo, M. F., Solís, D., André, S., Hirabayashi, J., Kasai, K.-I., Kaltner, H., Gabius, H.-J., & Romero, A. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.078 · Cited by 295
Self-citation
Metadata
- Authors
- André, S., Kaltner, H., Furuike, T., Nishimura, S.-I., & Gabius, H.-J.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2003-11-22
- Volume
- 15
- Issue
- 1
- Pages
- 87-98
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2086868992
- Cited by
- 164
- References
- 1
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.